Opaleye Management Inc. Relmada Therapeutics, Inc. Transaction History
Opaleye Management Inc.
- $411 Million
- Q1 2024
A detailed history of Opaleye Management Inc. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 759,000 shares of RLMD stock, worth $2.28 Million. This represents 0.86% of its overall portfolio holdings.
Number of Shares
759,000
Previous 759,000
-0.0%
Holding current value
$2.28 Million
Previous $3.53 Million
-0.0%
% of portfolio
0.86%
Previous 0.87%
Shares
3 transactions
Others Institutions Holding RLMD
# of Institutions
101Shares Held
14.3MCall Options Held
82KPut Options Held
73.9K-
Vanguard Group Inc Valley Forge, PA1.26MShares$3.77 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.24MShares$3.72 Million0.19% of portfolio
-
Vestal Point Capital, LP New York, NY1.2MShares$3.6 Million0.46% of portfolio
-
Acadian Asset Management LLC Boston, MA1.18MShares$3.54 Million0.02% of portfolio
-
Parsons Capital Management Inc974KShares$2.92 Million0.31% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $85.8M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...